You have searched for "2 Million Patient"
Showing 1-10 of 15
FRANKFURT/DUBLIN (Reuters) - Germany's drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs while Ireland has drawn up a watch list of some 24 medicines whose supply would be most vulnerable if Britain crashes out without a divorce deal.
Three years ago, artificial intelligence company DeepMind embarked on a landmark effort to transform health care in the UK. Now plans by owner Alphabet Inc to wrap the partnership into its Google search engine business are tripping alarm bells about privacy.
Alphabet Inc is merging part of its London-based artificial intelligence company DeepMind into sister company Google.
EMPLOYING 10 years of research and data collected from early users in the UK, MedPlanner is developing their second-generation communication app for collaboration between clinicians around the world to facilitate better communication and coordination in patient care delivery.
DeepMind, the London-based artificial intelligence company that is owned by Alphabet Inc, plans to develop a medical product that will help doctors to detect more than 50 sight-threatening conditions from a common type of eye scan.
Healthcare analytics have the potential to reduce costs of treatment, avoid preventable diseases and improve quality of patient care.
Deepmind, the digital brain foundry owned by Google's parent company, Alphabet, wants to use artificial intelligence to solve, well, everything. Last year, its software taught itself to play the strategy game Go better than any human on the planet. For its next trick, it wants to move beyond games to a very real-world problem: health care.
A landmark medical trial involving Alphabet Inc’s DeepMind artificial intelligence division violated British data protection laws, the UK’s top privacy watchdog ruled.
LONDON: Injecting Roche's cancer drug Avastin as a cheap eye treatment does not appear to increase deaths or serious side effects, according to an independent study that is likely to fuel a row over the medicine's unapproved use.